L. Jardines, B. G. Haffty, et al., “Breast Cancer Overview,” In: R. Pazdur, L. R. Coia, W. J. Hoskins and L. D., Wagman, Eds., Cancer Management a Multidisciplinary Approach, 9th Edition, CMPMedica, Lawrence, 2010, p. 163.
 Early Breast Cancer Trialists’ Collaborative Group, “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrenceand 15-Year Survival: An Overview of the Randomized Trials,” Lancet, Vol. 365, No. 9472, 2005, p. 1687. http://dx.doi.org/10.1016/S0140-6736(05)66544-0
 A. H. Partridge, H. J. Burstein and E. P. Winer, “Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women with Early-Stage Breast Cancer,” Journal of the National Cancer Institute, Vol. 2001, No. 30, 2001, pp. 135-142. http://dx.doi.org/10.1093/oxfordjournals.jncimono graphs.a003451
 B. F. Cole, R. D. Gelber, S. Gelber, et al., “Polychemotherapy for Early Breast Cancer: An Overview of the Randomised Clinical Trials with Quality-Adjusted Survival Analysis,” Lancet, Vol. 358, No. 9278, 2001, p. 277. http://dx.doi.org/10.1016/S0140-6736(01)05483-6
 J. Naurois, N. Basso, et al., “Management of Febrile Neutropenia: ESMO Clinical Practice Guidelines,” Annals of Oncology, Vol. 21, No. 5, 2010, pp. 252-256. http://dx.doi.org/10.1093/annonc/mdq196
 W. T. Hughes, D. Armstrong, G. P. Bodey, et al., “2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer,” Clinical Infectious Diseases, Vol. 34, No. 6, 2002, p. 730. http://dx.doi.org/10.1086/339215
 G. Bonadonna, E. Brusamolino, P. Valagussa, et al., “Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer,” The New England Journal of Medicine, Vol. 294, 1976, pp. 405-410. http://dx.doi.org/10.1056/NEJM197602192940801
 G. Bonadonna, P. Valagussa, A. Moliterni, et al., “Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer,” The New England Journal of Medicine, Vol. 332, 1995, pp. 901-906. http://dx.doi.org/10.1056/NEJM199504063321401
 J. N. Timmer-Bonte, E. M. Adang, H. J. Smit, et al., “Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis with Antibiotics in Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 24, No. 19, 2006, p. 2991. http://dx.doi.org/10.1200/JCO.2005.04.3281
 C. L. Vogel, M. Z. Wojtukiewicz, R. R. Carroll, et al., “First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients with Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study,” Journal of Clinical Oncology, Vol. 23, No. 6, 2005, p. 1178.
 J. H. Silber, M. Fridman, R. S. DiPaola, et al., “First-Cycle Blood Counts and Subsequent Neutropenia, Dose Reduction, or Delay in Early-Stage Breast Cancer Therapy,” Journal of Clinical Oncology, Vol. 16, 1998, pp. 2392-2400.
 E. Rivera, M. H. Erder and G. N. Hortobagyi, “First-Cycle Absolute Neutrophil Count Can Be Used to Improve Chemotherapy-Dose Delivery and Reduce The Risk of Febrile Neutropenia in Patients Receiving Adjuvant Therapy: A Validation Study,” Breast Cancer Research, Vol. 5, No. 5, 2003, pp. R114-R120. http://dx.doi.org/10.1186/bcr618